Pages that link to "Q47245555"
Jump to navigation
Jump to search
The following pages link to A post-licensure evaluation of the safety of inactivated hepatitis A vaccine (VAQTA, Merck) in children and adults (Q47245555):
Displaying 10 items.
- Hepatitis A immunisation in persons not previously exposed to hepatitis A (Q24202104) (← links)
- Hepatitis B and A vaccination in HIV-infected adults: A review (Q26799782) (← links)
- Concomitant administration of hepatitis A vaccine with measles/mumps/rubella/varicella and pneumococcal vaccines in healthy 12- to 23-month-old children (Q37530087) (← links)
- Neuromuscular complications of hepatitis A virus infection and vaccines (Q37797719) (← links)
- Long-term clinical observation of the immunogenicity of inactivated hepatitis A vaccine in children (Q51053523) (← links)
- Public health impact and cost effectiveness of routine childhood vaccination for hepatitis a in Jordan: a dynamic model approach. (Q52668904) (← links)
- Cost-effectiveness of hepatitis A vaccination for adults in Belgium (Q57515321) (← links)
- Hepatitis A vaccination effectiveness during an outbreak in the Ukraine (Q81296504) (← links)
- Influenza Vaccination Is Not Associated with Increased Number of Visits for Shoulder Pain (Q90106812) (← links)
- Safety and immunogenicity of VAQTA® in children 12-to-23 months of age with and without administration of other US pediatric vaccines (Q93092097) (← links)